Merck & Co. Inc. (MRK) Q3 2026 (USD) Adj. EPS 2.49 (exp. 2.09), Revenue 18.1bln (exp. 17.34bln), Current FY Adj EPS 2.77 (exp. 2.64), Current FY Rev. 66.8-67.3bln (exp. 67.05bln)
ORIGINAL · NewsquawkMerck & Co. Inc. (MRK) Q3 2026 (USD) Adj. EPS 2.49 (exp. 2.09), Revenue 18.1bln (exp. 17.34bln), Current FY Adj EPS 2.77 (exp. 2.64), Current FY Rev. 66.8-67.3bln (exp. 67.05bln)Read originalHide original
KEYTRUDA/QLEX Sales 8.601bln (+6% Y/Y). WINREVAIR Sales 694mln (+93% Y/Y). GARDASIL Sales 1.995bln (+14% Y/Y). Adj. Gross Margin 81.4% (prev. 81.9% Y/Y). FY 2026 revenue guidance raised and narrowed to 66.8–67.3bln (prev. 66.3–67.3bln), Adj. EPS guidance raised to 2.77–2.82 (prev. 2.66–2.76).
Merck’s Q3 adjusted EPS and revenue exceeded stated expectations; the report also listed product sales, a lower year-over-year gross margin, and raised FY 2026 guidance.
News detail
KEYTRUDA/QLEX Sales 8.601bln (+6% Y/Y). WINREVAIR Sales 694mln (+93% Y/Y). GARDASIL Sales 1.995bln (+14% Y/Y). Adj. Gross Margin 81.4% (prev. 81.9% Y/Y). FY 2026 revenue guidance raised and narrowed to 66.8–67.3bln (prev. 66.3–67.3bln), Adj. EPS guidance raised to 2.77–2.82 (prev. 2.66–2.76).
Related stocks
1 stocks
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.